EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

In Vitro and In Vivo Models for Drug Development Against Two Hemorrhagic Hareavirales: Rift Valley Fever and Crimean Congo Hemorrhagic Fever Viruses

Sarah Chaput iD, Antoine Nougairède, Franck Touret iD

Viruses · 19.03.2026 · 18 (3) · 386

DOI: 10.3390/v18030386 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 19.03.2026. Verfasst von Sarah Chaput und 2 weiteren Autor:innen. Beteiligte Einrichtung: Unité des Virus Émergents (UVE): Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA, 13005 Marseille, France. Hauptthemen laut MEDLINE: Rift Valley fever virus, Hemorrhagic Fever Virus, Crimean-Congo, Rift Valley Fever, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 217 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French Ministry of Defense—Defense Innovation Agency and Aix-Marseille University, French Research Institute for Developement (IRD) Chair “Antiviral strategy for emergence in the South”.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rift Valley fever virus (RVFV) and Crimean-Congo hemorrhagic fever virus (CCHFV) are designated by the World Health Organization as priority pathogens due to their epidemic potential, zoonotic transmission, and the absence of licensed therapeutics or vaccines. The development of effective antivirals critically relies on robust in vitro and in vivo models; however, progress is limited by the requirement for high-containment facilities. In this review, we provide a comprehensive overview of the experimental models currently available for RVFV and CCHFV, ranging from cell-based assays to animal models, and discuss their respective advantages, limitations, and translational relevance. We further highlight strategies allowing for BSL-2 experimentations, thereby expanding research accessibility, and accelerating the development of countermeasures against these high-priority pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rift Valley fever virusHemorrhagic Fever Virus, Crimean-CongoRift Valley FeverAntiviral AgentsHemorrhagic Fever, CrimeanDrug DevelopmentAnimalsDisease Models, AnimalHumans

Stichwörter der Autor:innen

Crimean-Congo hemorrhagic fever virusRift Valley fever virusantiviralshemorrhagic feverpreclinical models

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Unité des Virus Émergents (UVE): Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA, 13005 Marseille, France.

ORCID-Profile: Sarah Chaput, Franck Touret

Förderung

  • French Ministry of Defense—Defense Innovation Agency and Aix-Marseille University
  • French Research Institute for Developement (IRD) Chair “Antiviral strategy for emergence in the South”

Zitieren

APA

Chaput, S., Nougairède, A., & Touret, F. (2026). In Vitro and In Vivo Models for Drug Development Against Two Hemorrhagic Hareavirales: Rift Valley Fever and Crimean Congo Hemorrhagic Fever Viruses. Viruses, 18(3), 386. https://doi.org/10.3390/v18030386

Vancouver

Chaput S, Nougairède A, Touret F. In Vitro and In Vivo Models for Drug Development Against Two Hemorrhagic Hareavirales: Rift Valley Fever and Crimean Congo Hemorrhagic Fever Viruses. Viruses. 2026;18(3):386. doi:10.3390/v18030386

BibTeX
@article{Chaput2026,
  author = {Chaput, Sarah and Nougairède, Antoine and Touret, Franck},
  title = {In Vitro and In Vivo Models for Drug Development Against Two Hemorrhagic Hareavirales: Rift Valley Fever and Crimean Congo Hemorrhagic Fever Viruses},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {386},
  doi = {10.3390/v18030386}
}
Kostenlos starten →